- Home
- DSP vs ITOS Comparison
DSP vs ITOS Comparison
Compare DSP & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSP
- ITOS
- Stock Information
- Founded
- DSP 1999
- ITOS 2011
- Country
- DSP United States
- ITOS United States
- Employees
- DSP N/A
- ITOS N/A
- Industry
- DSP EDP Services
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DSP Technology
- ITOS Health Care
- Exchange
- DSP Nasdaq
- ITOS Nasdaq
- Market Cap
- DSP 291.3M
- ITOS 270.7M
- IPO Year
- DSP 2021
- ITOS 2020
- Fundamental
- Price
- DSP $12.24
- ITOS $7.32
- Analyst Decision
- DSP Strong Buy
- ITOS Strong Buy
- Analyst Count
- DSP 7
- ITOS 3
- Target Price
- DSP $23.29
- ITOS $26.00
- AVG Volume (30 Days)
- DSP 658.1K
- ITOS 370.8K
- Earning Date
- DSP 03-03-2025
- ITOS 03-05-2025
- Dividend Yield
- DSP N/A
- ITOS N/A
- EPS Growth
- DSP N/A
- ITOS N/A
- EPS
- DSP 0.14
- ITOS N/A
- Revenue
- DSP $289,235,000.00
- ITOS $35,000,000.00
- Revenue This Year
- DSP $13.31
- ITOS N/A
- Revenue Next Year
- DSP $16.25
- ITOS $121.70
- P/E Ratio
- DSP $86.47
- ITOS N/A
- Revenue Growth
- DSP 29.74
- ITOS 177.89
- 52 Week Low
- DSP $7.77
- ITOS $6.67
- 52 Week High
- DSP $26.33
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- DSP 24.79
- ITOS 50.93
- Support Level
- DSP $12.76
- ITOS $6.73
- Resistance Level
- DSP $13.77
- ITOS $7.65
- Average True Range (ATR)
- DSP 1.28
- ITOS 0.39
- MACD
- DSP -0.71
- ITOS 0.04
- Stochastic Oscillator
- DSP 4.39
- ITOS 66.33
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. Through the technology, a marketer can easily buy ads on desktop, mobile, connected TV, linear TV, streaming audio and digital billboards.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.